传染科指南

订阅

MedSci主页 / 所有栏目 / 传染科指南

2021 共识指南：抗真菌药物管理，监测和感染预防

2021-11-25 澳大利亚皇家医师学院 Intern Med J

侵袭性真菌病真菌组传抗真菌药物管理

侵袭性真菌病（IFD）是与高死亡率相关的严重感染，特别是在免疫功能地下的患者中。本文主要针对抗真菌药物管理，监测和感染预防提供指导建议。

中文标题：

2021 共识指南：抗真菌药物管理，监测和感染预防

英文标题：

Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021

发布机构：

澳大利亚皇家医师学院

发布日期：

2021-11-25

简要介绍：

侵袭性真菌病（IFD）是与高死亡率相关的严重感染，特别是在免疫功能地下的患者中。本文主要针对抗真菌药物管理，监测和感染预防提供指导建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 共识指南：抗真菌药物管理，监测和感染预防.pdf)] GetToolGuiderByIdResponse(projectId=1, id=5a8b01c002303060, title=2021 共识指南：抗真菌药物管理，监测和感染预防, enTitle=Consensus guidelines for antifungal stewardship, surveillance and infection prevention, 2021, guiderFrom=Intern Med J, authorId=0, author=, summary=侵袭性真菌病（IFD）是与高死亡率相关的严重感染，特别是在免疫功能地下的患者中。本文主要针对抗真菌药物管理，监测和感染预防提供指导建议。, cover=https://img.medsci.cn/20211227/1640573332665_5579292.jpg, journalId=0, articlesId=null, associationId=429, associationName=澳大利亚皇家医师学院, associationIntro=The RACP has various training pathways, linked to comprehensive training curricula, complemented by an extensive and wide-ranging program of on-the-job training, working with and learning from experienced clinicians. Becoming a Physician involves a significant amount of training, time and commitment and we have provided below some information on areas of interest and training options., copyright=0, guiderPublishedTime=Thu Nov 25 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">侵袭性真菌病（IFD）是与高死亡率相关的严重感染，特别是在免疫功能地下的患者中。本文主要针对抗真菌药物管理，监测和感染预防提供指导建议。</span></p>, tagList=[TagDto(tagId=12879, tagName=侵袭性真菌病), TagDto(tagId=120357, tagName=真菌组传), TagDto(tagId=120497, tagName=抗真菌药物管理)], categoryList=[CategoryDto(categoryId=9, categoryName=传染科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=12879, guiderKeyword=侵袭性真菌病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=9, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3749, appHits=186, showAppHits=0, pcHits=1171, showPcHits=3558, likes=0, shares=19, comments=17, approvalStatus=1, publishedTime=Mon Dec 27 10:43:31 CST 2021, publishedTimeString=2021-11-25, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Dec 27 10:54:42 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 18:56:23 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 共识指南：抗真菌药物管理，监测和感染预防.pdf)])
2021 共识指南：抗真菌药物管理，监测和感染预防.pdf
下载请点击：
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1210283, encodeId=8bd312102831b, content=谢谢分享！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7298109936, createdName=ms7000001140993293, createdTime=Mon Apr 11 13:32:56 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204723, encodeId=33fb1204e23b0, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/z9AUwkzqhABDln6bABnW52sMcs8aPhQTiadEGygLABibaeBfbd437Votsxfd8GMdyAsYSpYczFHPLs3kwoibra0SQ/132, createdBy=b6fb2340836, createdName=ms6903418467290158, createdTime=Mon Mar 21 20:41:00 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202471, encodeId=02cd12024e1fd, content=好内容, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17186550466, createdName=ms8000000510436154, createdTime=Mon Mar 14 14:16:08 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198068, encodeId=64cd1198068b2, content=好内容好资源！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13d36520323, createdName=ms6000000785802349, createdTime=Mon Feb 28 16:33:17 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186731, encodeId=f5771186e315e, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3818101931, createdName=wjl066452, createdTime=Fri Jan 21 10:13:33 CST 2022, time=2022-01-21, status=1, ipAttribution=)]
    2022-04-11 ms7000001140993293

    谢谢分享！

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1210283, encodeId=8bd312102831b, content=谢谢分享！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7298109936, createdName=ms7000001140993293, createdTime=Mon Apr 11 13:32:56 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204723, encodeId=33fb1204e23b0, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/z9AUwkzqhABDln6bABnW52sMcs8aPhQTiadEGygLABibaeBfbd437Votsxfd8GMdyAsYSpYczFHPLs3kwoibra0SQ/132, createdBy=b6fb2340836, createdName=ms6903418467290158, createdTime=Mon Mar 21 20:41:00 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202471, encodeId=02cd12024e1fd, content=好内容, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17186550466, createdName=ms8000000510436154, createdTime=Mon Mar 14 14:16:08 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198068, encodeId=64cd1198068b2, content=好内容好资源！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13d36520323, createdName=ms6000000785802349, createdTime=Mon Feb 28 16:33:17 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186731, encodeId=f5771186e315e, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3818101931, createdName=wjl066452, createdTime=Fri Jan 21 10:13:33 CST 2022, time=2022-01-21, status=1, ipAttribution=)]
    2022-03-21 ms6903418467290158

    受益匪浅

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1210283, encodeId=8bd312102831b, content=谢谢分享！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7298109936, createdName=ms7000001140993293, createdTime=Mon Apr 11 13:32:56 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204723, encodeId=33fb1204e23b0, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/z9AUwkzqhABDln6bABnW52sMcs8aPhQTiadEGygLABibaeBfbd437Votsxfd8GMdyAsYSpYczFHPLs3kwoibra0SQ/132, createdBy=b6fb2340836, createdName=ms6903418467290158, createdTime=Mon Mar 21 20:41:00 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202471, encodeId=02cd12024e1fd, content=好内容, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17186550466, createdName=ms8000000510436154, createdTime=Mon Mar 14 14:16:08 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198068, encodeId=64cd1198068b2, content=好内容好资源！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13d36520323, createdName=ms6000000785802349, createdTime=Mon Feb 28 16:33:17 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186731, encodeId=f5771186e315e, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3818101931, createdName=wjl066452, createdTime=Fri Jan 21 10:13:33 CST 2022, time=2022-01-21, status=1, ipAttribution=)]
    2022-03-14 ms8000000510436154

    好内容

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1210283, encodeId=8bd312102831b, content=谢谢分享！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7298109936, createdName=ms7000001140993293, createdTime=Mon Apr 11 13:32:56 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204723, encodeId=33fb1204e23b0, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/z9AUwkzqhABDln6bABnW52sMcs8aPhQTiadEGygLABibaeBfbd437Votsxfd8GMdyAsYSpYczFHPLs3kwoibra0SQ/132, createdBy=b6fb2340836, createdName=ms6903418467290158, createdTime=Mon Mar 21 20:41:00 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202471, encodeId=02cd12024e1fd, content=好内容, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17186550466, createdName=ms8000000510436154, createdTime=Mon Mar 14 14:16:08 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198068, encodeId=64cd1198068b2, content=好内容好资源！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13d36520323, createdName=ms6000000785802349, createdTime=Mon Feb 28 16:33:17 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186731, encodeId=f5771186e315e, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3818101931, createdName=wjl066452, createdTime=Fri Jan 21 10:13:33 CST 2022, time=2022-01-21, status=1, ipAttribution=)]
    2022-02-28 ms6000000785802349

    好内容好资源！

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1210283, encodeId=8bd312102831b, content=谢谢分享！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b7298109936, createdName=ms7000001140993293, createdTime=Mon Apr 11 13:32:56 CST 2022, time=2022-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204723, encodeId=33fb1204e23b0, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/z9AUwkzqhABDln6bABnW52sMcs8aPhQTiadEGygLABibaeBfbd437Votsxfd8GMdyAsYSpYczFHPLs3kwoibra0SQ/132, createdBy=b6fb2340836, createdName=ms6903418467290158, createdTime=Mon Mar 21 20:41:00 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1202471, encodeId=02cd12024e1fd, content=好内容, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17186550466, createdName=ms8000000510436154, createdTime=Mon Mar 14 14:16:08 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198068, encodeId=64cd1198068b2, content=好内容好资源！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13d36520323, createdName=ms6000000785802349, createdTime=Mon Feb 28 16:33:17 CST 2022, time=2022-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186731, encodeId=f5771186e315e, content=点赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3818101931, createdName=wjl066452, createdTime=Fri Jan 21 10:13:33 CST 2022, time=2022-01-21, status=1, ipAttribution=)]
    2022-01-21 wjl066452

    点赞

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

欧洲癌症研究和治疗组织(EORTC)及真菌研究组教育与研究共同体(MSGERC)关于侵袭性真菌病定义共识的修订及更新

暂未更新 · 2021-07-20

血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则（第六次修订版）

中国医师协会血液科医师分会 · 2020-10-10

器官移植受者侵袭性真菌病临床诊疗技术规范（2019版）

中华医学会器官移植学分会 · 2019-05-30

中国实体器官移植受者侵袭性真菌病临床诊治指南（2016年版）续

中华医学会器官移植学分会 · 2016-06-30